创新药物研发'风险投资-知识产权-研发外包'商业模式探讨

摘要

风险投资不足、知识产权流失严重以及研发外包发展停滞不前,严重阻碍了我国医药产业的创新发展.本文认为"风险投资-知识产权-研发外包" (VC+IP+CRO,VIC) 的商业发展模式能够推动我国创新药物的继续发展.在此基础上,本文对该模式形成的原因、运行机制以及优劣势进行了分析,并用案例证明了此种模式的可操作性.最后,提出了促进我国创新药物研发"VIC"商业模式发展的建议.%The lack of venture capital, loss of intellectual property rights and stagnation of outsourcing research and development ( R&D) industry set a serious impediment to the development of China's pharmaceutical innovation industry. This paper argues that the business model of "venture capital-intellectual property-contract research organization" ( VC + IP + CRO, VIC) can promote the sustainable development of innovative drugs in China. On this basis, this paper analyzes the causes, operating mechanism and advantages and disadvantages of the model, and proves the operability of this model with cases. Finally, the paper puts forward some suggestions to promote the development of "VIC"business model in the new drugs R&D in China.